Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000188451 | SCV000242065 | uncertain significance | not provided | 2021-04-20 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant does not alter protein structure/function; Has not been previously published as pathogenic or benign to our knowledge |
Labcorp Genetics |
RCV000576212 | SCV000677005 | uncertain significance | Developmental and epileptic encephalopathy, 12 | 2024-12-09 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with isoleucine, which is neutral and non-polar, at codon 419 of the PNKP protein (p.Val419Ile). This variant is present in population databases (rs756416098, gnomAD 0.007%). This variant has not been reported in the literature in individuals affected with PNKP-related conditions. ClinVar contains an entry for this variant (Variation ID: 206407). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt PNKP protein function with a negative predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV002415812 | SCV002681162 | uncertain significance | Inborn genetic diseases | 2019-11-15 | criteria provided, single submitter | clinical testing | The p.V419I variant (also known as c.1255G>A), located in coding exon 13 of the PNKP gene, results from a G to A substitution at nucleotide position 1255. The valine at codon 419 is replaced by isoleucine, an amino acid with highly similar properties. This amino acid position is well conserved in available vertebrate species. In addition, this alteration is predicted to be tolerated by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |
Breakthrough Genomics, |
RCV000188451 | SCV005194760 | uncertain significance | not provided | criteria provided, single submitter | not provided |